Clinical trials with CAR T cells targeting tumor-associated antigens in solid tumors, such as melanoma antigen recognized by T cells 1 (MART1) and glycoprotein 100 (gp100), showed that on-target off-tumor side effects do occur and sometimes cannot be easily reversed [26]. This evidence concerns the gene MLANA and neoplasm.